Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Fluorescent Skin Dye Offers Temporary Option for Skin Cancer Management

XTALKS VITALS NEWS

A team of researchers at the University of California, Los Angeles, have developed a novel fluorescent ink to temporarily tag the skin cancer lesion.

Share this!

January 4, 2017 | by Sarah Hand, M.Sc.

With the exception of melanoma, most types are skin cancer lesions are identified and tagged using small tattoos. While this method helps physicians track which areas need additional treatment, the long-lasting tattoo ink used can cause inflammation and can even be confused with lesions when a patient is being monitored in the future.

A team of researchers at the University of California, Los Angeles, have developed a novel fluorescent ink to temporarily tag the skin cancer lesion. Not visible by the naked eye, the dye only fluoresces under light with a wavelength of 465 nanometers.

“Tattooing has been utilized by the medical community for precisely demarcating anatomic landmarks,” said the study authors in their ACS Nano publication. “This practice is especially important for identifying biopsy sites of nonmelanoma skin cancer due to the long interval (i.e., up to 3 months) between the initial diagnostic biopsy and surgical treatment.”



Unlike the standard tattoo dye, the fluorescent ink fades over time. The researchers reported that the retention time of the dye was around 3 months, which coincides with the average time between a patient’s initial biopsy and when they receive surgical treatment.

The transdermal dye is composed of cross-linked fluorescent supramolecular nanoparticles and a fluorescent conjugated polymer center. The fluorescent dye has only been tested in mice, where it showed no propensity to trigger local inflammation.

According to the Canadian Cancer Society, nonmelanoma skin cancer is the most common form of the disease diagnosed in Canada. Statistics on the incidence of these types of skin cancer are, however, difficult to collect because diagnosis and treatment are often both done by a patient’s regular physician.


Keywords: Skin Cancer, Biopsy, Surgery


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Better Meal Planning for Diabetics Using a Predictive Blood Sugar App

April 21, 2017 - A new app could allow people with type 2 diabetes to make predictions about the impact of a meal on their blood sugar levels, before they even take a bite.

Featured In: Life Science News


Bacterial Biomarkers Could Make Diagnosing Colorectal Cancer Less Invasive

April 20, 2017 - Researchers at The University of Texas Health Science Center at Houston School of Public Health have identified specific strains of gut bacteria which have been associated with colorectal cancer.

Featured In: Life Science News


Weetabix Cereal Sold to Post in £1.4 Billion Deal

April 20, 2017 - The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Electronic Informed Consent: 2017 Industry Survey Results


Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-Time


The Modernization of eCOA Technology for Clinical Trials


Developing a Biological Safety Evaluation


Copyright © 2016-2017 Honeycomb Worldwide Inc.